In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4
- PMID: 39496171
- DOI: 10.7326/ANNALS-24-02625-JC
In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4
Abstract
Lopes RD, Granger CB, Wojdyla DM, et al. Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024;84:354-364. 39019530.
Conflict of interest statement
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
- Miscellaneous
 
        